# Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

> **NCT05363293** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alzamend Neuro, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Alzheimer's Disease
- Healthy Non-elderly and Elderly Adults

## Interventions

- **DRUG:** AL001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05363293
- **Lead sponsor:** Alzamend Neuro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-04
- **Primary completion:** 2023-04-14
- **Final completion:** 2023-05-15
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363293, "Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05363293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*